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Adverse Outcome Pathway External Review Report 
AOP 42: Inhibition of thyroperoxidase and subsequent Adverse Neurodevelopmental 
Outcomes in Mammals 
 
Short title : TPO Inhibition and Altered Neurodevelopment 
 
 
      
 
 
This AOP 42 list six key events leading from the molecular initiating event (MIE) inhibition of Throperoxidase to the 
decreased cognitive function (AO). The proposed AOP states that the MIE (E 279) subsequently leads to 1) a 
decreased TH synthesis (KE 277)  which leads to 2) a decrease in T4 in serum (KE 281) which leads to 3) a decrease in 
T4 levels in neuronal tissue (KE 280) and 4) alters hippocampal gene expression (KE756) which in turn leads to 5) an 
altered hippocampal morphology (KE757) and therefore -6) a decreased in hippocampal function (KE758) to finally 
adversely affect  cognitive function (AO).  
This document is the final report established in May 2018 of an external review started in January 2018. It reflects 
reviewers’ comments, answers from the authors and revisions planned regarding AOP42. 
The review panel all agreed on the high quality of the work done on AOP42.  Even before any revisions, almost all 
reviewers agreed that it was constructed based on the OECD Guidance and Handbook.  The reviewers developed a 
number of suggestions and corrections that were discussed in joint meeting with the authors.  This discussion between 
the reviewers and the authors led to good agreement on required changes. All of these changes have now been 
incorporated into the newly revised AOP42.  We now all find that the revised AOP42 is ready for final OECD approval 
and for regulatory applications in a near future. 
 
 
      
 
  
 
 
  
This document, as well as any data and map included herein, are without prejudice to the status of or sovereignty over any territory, to the 
delimitation of international frontiers and boundaries and to the name of any territory, city or area. 
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1.  Introduction and background to specific AOP 
OECD AOP 42 Inhibition of thyroperoxidase and subsequent Adverse 
Neurodevelopmental Outcomes in Mammals” with the short title: TPO Inhibition and 
Altered Neurodevelopment can be found at  https://aopwiki.org/aops/42.  
 
This AOP establishes the link between the disruption of thyroperoxidase (TPO), key 
enzyme of thyroid hormone (TH) organization and neurodevelopmental consequences.  
The authors of this AOP are :  
Kevin M. Crofton, National Center for Computational Toxicology, US EPA, RTP, NC 
USA crofton.kevin@epa.gov ; Mary Gilbert, National Health and Environmental Effects 
Research Laboratory, US EPA, RTP, NC USA gilbert.mary@epa.gov ; Katie Paul 
Friedman, National Center for Computational Toxicology, US EPA, RTP, NC USA paul-
friedman.katie@epa.gov ; Barbara Demeneix, UMR MNHN/CNRS 7221 Evolution of 
Endocrine Regulations, National History Museum, Paris, France bdem@mnhn.fr ; Mary 
Sue Marty, Toxicol. Environ. Res. Consult, Dow Chemical Company, Midland, 
Michigan; mmarty@dow.com; R. Thomas Zoeller, Biology Department, University of 
Massachusetts, Amherst, MA tzoeller@bio.umass.edu.  
 
This AOP describes one adverse outcome that may result from the inhibition of 
thyroperoxidase (TPO) during mammalian development. Chemical inhibition of TPO, the 
molecular-initiating event (MIE 279), results in decreased thyroid hormone (TH) 
synthesis (KE277), and subsequent reduction in circulating concentrations of THs 
(KE281) and consequently a decrease in neuronal TH levels (KE 280). THs are essential 
for normal human brain development, both prenatally and postnatally, modulating genes 
critical for a normal neuroanatomical development, with subsequent effects on 
neurophysiology, and finally neurological function. Therefore, chemicals that interfere 
with TH synthesis have the potential to cause TH insufficiency that may result in adverse 
neurodevelopmental effects in offspring.  
The hippocampus is known to be critically involved in cognitive, emotional, and memory 
function. The adverse consequences of TH insufficiency depend both on severity and 
developmental timing, indicating that exposure to TPO inhibitors may produce different 
effects at different developmental windows of exposure. Herein, authors discuss the 
implications of developmental TPO inhibition for hippocampal anatomy (KE 757), 
function (KE 758), and ultimately neural function controlled by the hippocampus. The 
biochemistry of TPO and its essentiality for TH synthesis is well known across species.  
It is important to note that thyroid stimulating hormone (TSH) is not a KE in this AOP. 
While TSH may play a role in feedback-driven compensatory processes, it is not directly 
involved in brain development. The overall weight of evidence for this AOP is strong. 
Gaps in current understanding include the relationship of TH-dependent gene expression 
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and complexities of brain development. Although quantitative information at all levels of 
KERs is limited a number of applications of this AOP have been identified.  
The graphical representation of the AOP is accessible on the figure 1 
The snapshot generated at the end of 2017 was submitted for an external review.  
This AOP was last updated May 2018. 
 
 
Figure 1: Graphical representation of AOP 42 Inhibition of thyroperoxidase and 
subsequent Adverse Neurodevelopmental Outcomes in Mammals   
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2.  Synthesis of main issues of the review 
Five independent volunteer reviewers were selected among many skilled candidates. 
Selection was driven by their expertise in thyroid signalling regulations and or health 
consequences. Particular concern was taken in balancing reviewers from academy, 
industry and from different countries around the world. 
AOP 42 has been reviewed during january/february 2018 by a team of 5 reviewers:  
 Dr Angela Leung (University UCLA_ USA) 
 Dr Ellen Hessel (RIVM_Netherlands) 
 Dr Marta Axelstad (DTU_Danemark) 
 Dr Alexius Freyberger (Bayer_Germany ) 
 Pr Frances Carr (University of Vermont_USA) 
 
Reviewers, were asked to reply to the following questions related to different aspects of 
the AOP:  
1.       Scientific quality: 
•       Does the AOP incorporate the appropriate scientific literature? 
•       Does the scientific content of the AOP reflect current  scientific knowledge on 
this specific topic? 
2.       Weight of evidence:  
•       Are the weight-of-evidence judgement/scoring calls provided by AOP developers 
for KEs, KERs and the overall AOP justified? 
3.       Regulatory applicability:  
•       Considering the strength of evidence and current  gaps / weaknesses, what would 
be the regulatory applicability of this AOP, in your opinion? 
4.       Conclusion:  
•       What are your overall conclusions of the assessment of this AOP? 
. 
The version reviewed was the snapshot generated at the end of 2017.  
The last update done on this AOP was done in May 2018. 
2.1. Scientific quality: 
Reviewers all agree on the high quality of the AOP. They acknowledge authors as experts who have 
published, for many of them, fundamental articles in the field of thyroid hormones and their mechanisms 
of regulation. 
Before the TC, reviewers did not all agree on the direct application of the AOP for regulatory purposes.  
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Other points raised by the reviewers needed further discussion. For example, key event specificity 
between MIE and AO (when comparing to AOPs sharing an adverse outcome). More generally, 
discussion on the specificity of T4 decrease and a focus on hippocampus were needed. Further, 
conflicting studies were asked to be referenced or discussed.  
 
Does the AOP incorporate the appropriate scientific literature? Does the scientific content of the AOP 
reflect current scientific knowledge on this specific topic? 
 
Even before the teleconference and the revision of the AOP operated by the authors, all reviewers agreed 
on the very high quality and relevance of scientific literature cited which covered the content of the AOP 
and supported the biological plausibility of the pathway. All reviewers agreed that missing information 
comes generally from knowledge gaps and were very well presented by authors.  
Classification of evidence with upstream and downstream events was justified and appropriate.  
Two main points were raised. One about TPO inhibition would do not necessarily lead to a TH decrease. 
Second point raised was about the BDNF decrease (KE 381) stated as a key event in AOP 54. As those 
two AOPs share the same adverse outcome and some key events, one reviewer was wondering why not 
considering KE 381 in the AOP 42. 
 
Specific points raised by the reviewers are listed below and have been discussed at the teleconference 
(TC). Extensive reviews were provided by the five reviewers. The complete reviews can be found in 
Annex 2.  
Note that the order of the reviewers given in section 1 is not in accordance with the numbers given (R#) 
in quotations provided all along the report.  
 
 
MIE _ TPO inhibition (E 279) 
The multifactorial origin of TH disruption is acknowledged in this AOP (R#1, R#3).  Nevertheless, the 
fact that other factors could balance the response of a given stressor should be discussed further.  
Differences of sensitivity to decreased levels of TH depend on moment of exposure and the storage 
capacity of iodine and thyroid hormones. Specifically:  
 Impact of Tg antibodies or age (R#1) is currently missing.  
 Iodine deficiency or thyroid status at stressor exposure needs discussing :  
o R #1 highlights that  many factors influence iodine intake (age, diet ..) and that 
differential iodine storage capacities varies with life stages should be notified in the AOP 
o R#5 reminds everyone, that strong reduction of thyroxine levels with genistein was not 
associated with cognitive impairment unless an iodine defect exists. R#5 also suggests to 
add a specific point on fetal TPO and brain/ hippocampal development (and the 
associated knowledge gap).  
R#5 describes why the term “TPO inhibition” is misleading as it is used in a too broad sense within the 
AOP. Therefore, either another term is used or it should be stated that TPO inhibition also covers 
interactions with iodinating species. 
 
Key Events 
KE 281-T4 in serum, decrease:  
R#4 highlights the need to recommend some standardized methodologies for TH measurements as there 
are numerous (HPLC, MS, ELISA, RIA) with different sensitivities.  
R#4 asks to mention that blood sampling should be controlled for external factors such as circadian 
rhythms and food intake.  
An important point raised by R#3 and #4 is the crucial need for standardized methodologies and ask 
authors to specify if one is preferred among all existing techniques and why. 
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KE 280 T4 in neuronal tissue, decrease _ 
As circulating TH levels are not necessarily reflecting brain TH levels, TH levels are different within 
brain structures. Therefore, the dissection method is crucial for reproducibility and should be clearly 
mentioned (R#4). 
 
KE 756-Hippocampal gene expression 
R#2 is questioning why BDNF expression, which is a key event in AOP54, is not referred here. 
Harmonization between the two AOPs is necessary. Therefore, harmonisation of KEs or why this KE is 
not relevant to the present AOP should be discussed at the TC. 
R#3 agrees with the authors on the emphasis placed on the hippocampus given the most scientifically 
available literature but reminds that decreased cognitive function could have multiple origins. 
R#4 states that genome wide profiles or microarray studies are not specific enough to measure the effect 
of TH levels on gene expression. A prerequisite on hypothyroid hippocampus gene expression would be 
needed. 
 
KE 757- Hippocampus anatomy altered 
R#4 mentions that the methods available to measure this KE are not specific enough. Focus must be on 
thyroid hormone specific alterations of the anatomy of the hippocampus. Moreover R#4 suggests to add a 
small section on the importance of maternal thyroid status for hippocampal development, suggestion 
meeting R#5 request on fetal TPO importance (see MIE).  
 
KER (Key Event Relationship) 
Two reviewers are calling for the inclusion of existing studies showing moderate to severe decreases in 
circulating TH, leading to minor or undetectable adverse effects on brain morphology in the offspring 
(R#2 and R#5). 
Regarding decreased T4 in neuronal tissues which directly lead to altered hippocampal gene expression: 
R#1 asks if any quantifiable data could be added between levels of TH in serum and in brain and gene 
expression.  
As there is no quantitative data which supports the current KER in the AOP, “no data” instead of “weak” 
should be mentioned (R#5) 
R#2 supports addition of an intermediate step on local deiodination as this step is crucial for altered gene 
expression. 
 
TPO inhibition indirectly leads to “T4 serum, decreased”:  
R#5 reminds that even with a 80% inhibition of TPO, no effects were observed on TH levels in rat. 
Further, R#1 and R#3 agree with the authors on the fact that TSH levels measurements are not relevant to 
this AOP.  
 
Other suggestions:  
Precludes the use of “accepted dogma” or “well accepted in endocrinology” eg p39 and 62 (R#2). 
Discuss non-genomic effects R#1 
Use CAS numbers for the stressors to avoid any confusion due to differences in spelling (R#5)  
Add a comparison of TPO across species (R#5) 
TH levels are different within brain structures. Therefore the dissection method is crucial for 
reproducibility and should be clearly mentioned (R#4). 
 
More details and useful suggestions are accessible within individual reviews (below and in annex2).  
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2.2 Weight of evidence 
Are the weight-of-evidence judgement/scoring calls provided by AOP developers for KEs, KERs and 
the overall AOP justified ? 
 
All reviewers consider that weight of evidence is overall well balanced and appropriate. Uncertainties 
and inconsistencies are very well written and appropriately noted. The limitations of quantitative 
understandings of the KE are addressed.  
However, two reviewers consider that WoE for the direct link between T4 decrease and hippocampal 
gene expression defects or anatomy is weak. R#2 suggests to add another “local conversion”.  
R#4 thinks that the link referred to as “moderate” by the authors for TH levels to hippocampal gene 
expression to hippocampus anatomy should be downgraded to “weak” as more scientific evidence is 
required. R#5’s suggestion is to state “no data” when no quantitative data could be provided. 
Conflicting views on the modifications to make regarding the evidence of key event relationships need to 
be discussed. R#1, R#3 and R#5 considered that the weight of evidence is appropriate, R#2 suggests to 
reorganize the literature cited by emphasizing TH serum levels and effects on the brain whereas R #4 
highlights the need of a stronger direct causal link between T4 decrease and hippocampal gene 
expression or anatomical defects.  
 
2.3 Regulatory applicability: 
Considering the strength of evidence and current gaps/weaknesses, what would be the 
regulatory applicability of this AOP, in your opinion? 
 
Before the teleconference and the revision of the AOP, divergent opinions arose as to the applicability of 
the AOP for regulatory purposes. Reviewer # 1 considered that the regulatory application could be 
quickly achieved whereas reviewers # 2 # 3 # 4 considered that a regulatory application is limited as long 
as quantifications for the two endpoints mentioned by the authors are not achieved and standardized. 
Nevertheless, reviewers mentioned the possibility of direct applications for screening tests, either on 
neurotoxicity or for identification of endocrine disruptors. Reviewer # 5 was more critical of the direct 
applicability at the regulatory level, the idea being that a percentage of TPO inhibition is needed to 
trigger the cascade of events described in AOP42 and that negative cases exist and should be mentioned 
(in reference to the genistein case). 
 
2.4 Conclusion: 
What are your overall conclusions of the assessment of this AOP? 
All the reviewers agreed on the well written and documented AOP. The gaps allowing for a strong 
relationship of the KERs were already identified by the authors. The suggestions mentioned by the 
reviewers would allow for improvement of an already very complete document. It is worth mentioning 
that this AOP will have to be updated regularly in order to include recent fundamental and technical 
knowledge that will fill the caveats due to the current state of knowledge. Discussions about the 
importance of quantifying /identifying threshold MIE and KE, the relationship between TPO inhibition 
and consequent effects on the hippocampus were needed at the TC. 
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3.  Summary record of the teleconference 
3.1 TC agenda 
Agenda for the teleconference May 18
th
  
 
2pm- 2:45 pm_Specific points on AOP 54 
 
 Presentation of specific comments related to AOP54 (reviewer manager) 
 Charge question by charge questions reviewer comments  
 Authors reply 
 AOB 
 
2:45pm -3:30pm_ Overlapping issues on the two AOPs 54 (NIS) and 42 (TPO) 
 
 Brief overview of both AOP 54 and 42 (Reviewer manager) 
 Comments on common key events: TH synthesis decreased, T4 in serum decreased, TH in 
neuronal tissue decreased  
 How addressing AOPs sharing Key event(s) AND adverse outcome(s) with different 
intermediary key events? 
 
3:30 pm- 4:15 pm_Specific points on AOP 42 
 Presentation of specific comments related to AOP42(reviewer manager) 
 Charge question by charge questions reviewer main comments  
 Authors reply 
 AOB 
 
3.2 Main issues and responses during the call 
At 2.45pm participants were  
Reviewers: Ellen Hessel (EH), Francesca Carr (FC), Angela Leund (AL), Marta Axelstad (MA). At 2.45 
Alexius Freyberger joined. 
Authors AOP 54 Anna Price (AP) and Francesca Pistollato (FP) with one connection from JRC. 
Authors AOP 42 Kevin Crofton (KC) and Mary Gilbert (MG) 
Chair: Jean-Baptiste Fini (JBF) 
 
Note that reply from the authors during the TC are in bold.  
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The dedicated call started at 2.45pm with overlapping issues between AOP42 and 54. 
Nevertheless AOP42 authors participated from the beginning when discussing the AOP54 
specific points (2pm) 
Importantly, when discussing the BDNF related KE in specific AOP54points, KC and MG agreed with 
AP who discussed the fact that AOPs are all different and they could have common KE with 
different connections at one moment. They also mention the AOP network organization which will 
take place within the ongoing process: 
  
Two reviewers put forward that BDNF levels were mainly driven by accessibility of human data in 
contrast to other consequences of TH decrease. Plausibility of a hippocampal deficit being stronger than 
that of BDNF reduction, shall a focus on hippocampus and/or cortex be preferable? _ this point 
generated an intense discussion.  Main argue from the authors (AOP 54 but also 42 present) were 
that AOP are unique and if one wants to link BDNF with hippocampus gene expression, therefore 
another AOP should be constructed. Both, AOP54 authors and AOP42 mentioned that the AOP 
network linking the two AOP will be a future step in the AOP process. Giving these elements all 
attendees decided to maintain the AOP in their present form. 
 
When comparing AOP 54 with 42, one could see that right after the two different molecular initiating 
events, three KE are common: KE 277 TH synthesis, decreased; KE 281 T4 in serum, decreased ; KE 280 
T4 in neuronal tissue, decreased (see Figure 2). After KE 280 there are two divergent key events which 
are KE 756 hippocampal gene expression, altered; and KE 381 reduced levels of BDNF.  
 
 
Figure 2: Comparison of the two graphical abstracts if AOP42 and54. Red circles show common 
KEs between the two AOPs. Note that the AOP42 graphical abstract is truncated and is not the 
final version (missing indirect KERs) 
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On KE 281 T4 in serum, decreased.  
On that specific point reviewers highlighted the need to recommend some methodologies for TH 
measurements as there are numerous (HPLC, MS, ELISA, RIA) with different sensitivities. 
KC, MG and AP agreed on the fact that AOP authors are not supposed to suggest, promote 
technologies and that it is not what they need to do in KE description. They agreed that the 
different technologies should be listed but not detailed. Giving these elements, reviewers 
validated the current presentation of KE281. A related point raised by two reviewers was a “need 
for standardized methodologies”. Due to the previous discussion this point was cleared. 
On KE 280: T4 in neuronal tissue, decreased 
One reviewer mentioned that TH levels being different within brain structures, dissection method 
is crucial for reproducibility and should be clearly mentioned. However giving the discussion 
which took place at the beginning of the TC on what authors have to provide, we all decided 
that this was not the role of authors to promote a technique even though everybody agreed 
on the relevance of the issue raised. 
One major issue was also the “harmonization between AOPs?” 
The divergence after T4 levels in neuronal tissue leading to KE 756 hippocampal gene 
expression, altered; and KE 381 reduced levels of BDNF.  
JBF suggested that when two AOPs have different KEs which lead to similar late KEs or AO a 
branching could be considered  
Another suggestion was to consider that KE 381 as part of KE756 if considering only 
hippocampus. These considerations were discussed but as already stated AOP 42 and 54 are 
considered different and independent. Everybody agreed that these pathways could stand 
separate.  
Last point of harmonization was on the tables showing divergent weight of evidence and 
quantitative understanding of AOP KERs. For the common KERs, different evidence weights are 
given. In AOP54 “Thyroid hormone synthesis decreased” leading to “T4 in serum decreased”, 
evidence and quantitative understanding were respectively strong and strong whereas in AOP42 
evidence and quantitative understanding were strong and moderate.  
Regarding the KER “thyroid in serum decreased” leading to “decreased T4 levels in neuronal 
tissue” evidence and quantitative understanding for AOP 54 were strong and weak but moderate 
and weak in AOP42. AOP 54 authors agreed to adapt AOP54 in order to fit with AOP42.  
 
Second part of the TC 
Then, at 3.30pm specific issues were raised on AOP42. 
KC and MG deeply thanked the reviewers for their hard work on the reviews which make the 
AOP improve.  
JBF used slides to support discussion on the points raised by the 5 reviewers (see Annex 4 for the 
slides) 
All reviewers agreed on the high quality of the AOP42 provided. KC and MG deeply thanked the 
reviewers for their work and suggestions on the AOP which will definitively improve the 
document. 
Main issues discussed:  
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1) the “genistein effect” on TPO with no subsequent effect on cognitive impairment to be 
discussed within the AOP 
2) Addition of a new KE: local deiodination decreased 
 
 MIE Thyroperoxidase inhibition.  
During the review process R#5 raised the point that Denomination TPO inhibition is considered 
to be used in a too broad sense.  Authors agreed with the suggestion made to modify the AOP in 
incorporating that TPO inhibition also covers TPO-iodinating species 
Still on the MIE, others suggestions were made to consider confounding effects on TPO effects. 
Namely: Given that sensitivity to decreased levels of TH depends on moment of exposure and the 
storage capacity of iodine and thyroid hormones. Reviewers suggested to add in the KE 
description :   
• Impact of Tg antibodies or age  
And to discuss in more details:  
• factors influence iodine intake (age, diet ..) differential iodine storage capacities 
varies with life stages  
• reduction of thyroxine levels with genistein were not associated with cognitive 
impairment unless an iodine defect exists.  
 
Authors did not fully agree with these suggestions. While they agree that there is evidence that 
iodine and antibody status can impact thyroid hormone synthesis and homeostasis, they disagree 
that these items should be addressed in this AOP as AOP is not designed for iodine deficiency or 
any other of the multitude of dietary conditions (e.g., iron, selenium) or other factors external to 
the KEs in this AOP. 
For the genistein they agreed that this specific example should be mentioned. 
• Direct fetal TPO inhibition and consequent brain/ hippocampal development in 
human should be mentioned  (and the associated knowledge gap).  
Authors agreed to integrate the changes in the AOP. They will do it at MIE, but also in 
uncertainties and inconsistencies for two KERs :TPO and serum TH  but also serum T4 
and hippocampal anatomy. 
KE  Hippocampal gene expression 
• R#3 agrees with the authors on the emphasis placed on the hippocampus given the most 
scientifically available literature but reminds that decreased cognitive function could 
have multiple origins. 
• R#4 states that genome wide profiles or microarray studies are not specific enough to 
measure the effect of TH levels on gene expression. A prerequisite on hypothyroid 
hippocampus gene expression would be needed.  
Authors agreed to take in consideration these comments and add a comment in the AOP. 
KER TPO and T4 serum decreased 
Genistein case: In Chang & Doerge 2000 and Doerge &Chang 2002, genistein administration 
was shown to lead to  80% inhibition of TPO activity but no effects observed on TH levels in rat. 
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This was asked to be added  in uncertainties and inconsistencies. The authors agreed with 
this comment from the reviewer and altered the text accordingly, as suggested. 
KER T4 serum decreased and cognitive function decreased 
Two reviewers are calling for the inclusion of existing studies showing moderate to severe 
decreases in circulating TH, leading to minor or undetectable adverse effects on brain 
morphology in the offspring.  
Authors agreed that quantitative relationship between decrease of thyroxine and a 
neurodevelopmental adverse outcome is poorly understood. There are insufficient data to 
describe quantitative relationships owing not only to the state of knowledge of TH role in 
hippocampal morphology and the requisite contributions from maternal, fetal, neonatal sources 
when specific phases of hippocampal neuroanatomical development occur.  
Therefore, authors suggested to add a comment in that sense in the AOP. 
 
New Key event to be added Between T4 in neuronal tissue and hippocampal gene expression:  
• Suggestions to add the KE related to local deiodination decreased (KE 1002?). Authors 
agreed that deiodinases play an essential role in maintaining appropriate concentrations 
of TH in brain and other organs. But they also remind that there is no “complete AOP”: 
For this AOP there could be multiple steps added for complete TH synthesis pathway, as 
well as steps for release from thyrocytes, uptake from blood into tissues via cellular 
transporters, interaction with serum binding proteins, etc. _Authors planned to 
introduce a description of the importance of deiodinase in the AOP but not include 
a new KE. 
• Quantifiable data should be added between levels of TH in serum and in brain and gene 
expression. _Authors agreed on amending the AOP42 on that specific point. 
• If no quantitative data supports the current KER in the AOP, there is a suggestion to 
mention “no data”_ This is not an option in the AOP Wiki as strength indicators are 
dictated by OECD’s AOP Handbook and guidance document. 
Regulatory considerations 
Before discussing the last part on regulatory aspect, JBF reminded everyone that AOP are living 
document. As methods for observing biology evolve, new possibilities for KEs arise. 
Importantly, there is no objective of a “complete AOP” 
Before the TC, divergent opinions arose as to the applicability of the AOP for regulatory 
purposes.  
As a reminder : Reviewer # 1 considered that the regulatory application could be quickly 
achieved, reviewers # 2 # 3 # 4 considered that a regulatory application is limited as long as 
quantifications are not achieved and standardized. Reviewer # 5 was more critical of the direct 
applicability at the regulatory level, the idea being that a percentage of TPO inhibition is needed 
to trigger the cascade of events described in AOP42.  
At the end of the TC, thanks to authors reply and planned revisions all agreed on the direct 
applicability of the AOP 42 for regulatory purpose. 
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At the end of the TC, and a consensus agreement was found in planning to do the revisions 
discussed in short time frame. Action list was given. 
No further questions. Authors thanked again reviewers and review manager for the work on 
review and TC. 
 
3.3 Action list 
There were actions to be done in the following days to be able to send the final report at 
the OECD. 
1) JBF: to send the slides to everyone  
2) KC and MG and answer the mains issues raised by the reviewers and to provide a 
revised AOP (see section 4). Specifically:  
a. Add a discussion on genistein case 
b. Add a discussion on deiodinase function in neuronal tissue 
3) All: to agree on the revisions 
4) KC and MG to incorporate the modifications on AOP wiki 
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4.  Summary of planned revisions  
Following the TC authors provided a detailed table answering point by point to the main 
issues raised and discussed at the TC. 
 
Response to Reviewers Comments  
Section 1:  Comments from Slides and Discussion during Conference Call  
Reviewer Comment Author Response Changes to AOP42 
Denomination TPO inhibition 
is considered to be used in a 
too broad sense along the 
review. There is a suggestion 
to mention that TPO 
inhibition also covers TPO-
iodinating species.  
Authors agree and thank Reviewer for 
suggestion. Term was invoked as It has 
normally been applied in the toxicology 
literature, especially recent high-
throughput screening.  
Page 17 revised doc following has been 
added: 
It is important to note that TPO is a 
complex enzyme and that has two catalytic 
cycles and is capable of iodinating multiple 
species (Divi et al., 1997). Alterations in all 
of these events are not necessarily covered 
by some of the commonly used assays that 
measure “TPO inhibition” (e.g., guaiacol 
and AmplexUltraRed, see below).  
Therefore, in the context of this AOP we are 
using TPO inhibition not in the classical 
sense, but instead to refer to the empirical 
data derived from the assays commonly 
used assays to investigate environmental 
chemicals. 
 
Given that sensitivity to 
decreased levels of TH 
depends on moment of 
exposure and the storage 
capacity of iodine and thyroid 
hormones. Reviewers suggest 
to add/discuss in more detail 
in KE description   
 Impact of Tg antibodies 
or age  
• factors influence iodine 
intake (age, diet ..) 
differential iodine 
storage capacities varies 
with life stages  
While we agree that there is plentiful 
evidence that iodine and antibody status 
can impact thyroid hormone synthesis 
and homeostasis, we disagree that these 
items should be addressed in this AOP.  
The AOP is not designed for iodine 
deficiency or any other of the multitude 
of dietary conditions (e.g., iron, 
selenium) or other factors external to 
the KEs in this AOP.   
 
For genistein – please see comments 
below in response to slide 5.  
No changes to be made. 
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• reduction of thyroxine 
levels with genistein 
were not associated with 
cognitive impairment 
unless an iodine defect 
exists.  
Direct fetal TPO inhibition 
and consequent brain/ 
hippocampal development in 
human should be mentioned 
(and the associated 
knowledge gap).  
 
Agree this is an important point to 
clarify. The direct action of TPO 
inhibitors on the fetal as well as the 
maternal thyroid gland has been 
addressed in three places in the revised 
document 
Page 18 – MIE – Uncertainties and 
Inconsistencies. It is noted that prior to the 
onset of fetal thyroid function, TH are still 
required, the fetus relying solely on 
maternal sources. Chemical-induced TPO 
inhibition can affect synthesis in the 
maternal gland and in the fetal gland. 
Page 74 – Uncertainties and Inconsistencies 
KER TPO inhibition and serum TH. The 
relationship between maternal and fetal 
levels of hormone following chemically-
induced TPO inhibition has not been well 
characterized and may differ based on 
kinetics. Reductions in serum TH in the 
fetus, in rat and human is derived a 
chemical’s effect on the maternal thyroid 
gland as well as the fetal thyroid gland.  
Page 118 – Uncertainties and 
Inconsistencies in indirect KER Serum T4 
and Hippocampal Anatomy. The role of 
direct fetal TPO inhibition contribution to 
fetal TH and subsequent changes to 
hippocampal structure and subsequent 
downstream KEs in humans is a knowledge 
gap.   
 
Hippocampal gene expression 
R#3 agrees with the authors 
on the emphasis placed on 
the hippocampus given the 
most scientifically available 
literature but reminds that 
decreased cognitive function 
could have multiple origins. 
 
Agreed that hippocampus is not the 
only structure underlying cognitive 
function, the authors did not mean to 
suggest so. 
We point to several places in the 
document where regional specificity of 
brain function is mentioned that 
underscore that cognition is 
multifaceted 
Pg 47: Through the interconnectivity 
within the hippocampus and its 
connections to amygdala, septum and 
cortex, the hippocampus plays a pivotal 
role in several learning and memory 
processes, including spatial behaviors 
We have added the following disclaimer to 
the summary section of the document to 
emphasize this point. 
 
Page 127. Indirect KER SerumT4 to 
Cognitive Function 
Clearly the brain circuitry controlling 
cognitive function is complex and is not 
solely accomplished by the functionality of 
the hippocampus. However, it is well 
documented that normal hippocampal 
structure and physiology are critical for the 
development of cognitive function. 
      │ 17 
 
ADVERSE OUTCOME PATHWAY EXTERNAL REVIEW REPORT 
  
 
Pg 56: Learning and memory depend 
upon the coordinated action of different 
brain regions and neurotransmitter 
systems constituting functionally 
integrated neural networks (D’Hooge 
and DeDeyn, 2001). Among the many 
brain areas engaged in the acquisition 
of, or retrieval of, a learned event, the 
hippocampal-based memory systems 
have received the most study. 
Pg 105. However, the causative 
relationship of which specific 
alterations in synaptic function are 
associated with specific cognitive 
deficits is difficult to ascertain given the 
many forms of learning and memory, 
and the complexity of synaptic 
interactions in even the simplest brain 
circuit.  
 
Hippocampal Gene 
Expression 
R#4 states that genome wide 
profiles or microarray 
studies are not specific 
enough to measure the effect 
of TH levels on gene 
expression. A prerequisite on 
hypothyroid hippocampus 
gene expression would be 
needed. 
 
 
 
While we agree that measurement of 
gene levels is not indicative of changes 
in protein level, the data in this arena is 
scarce and we include all that is 
available.   The data included in the 
Table on page 109 of Word document 
describes gene transcripts identified in 
fetal and neonatal brain in 
hippocampus, cortex and cerebellum. 
Although derived from wide genome 
profile searches, most were from rtPCR 
of individual transcripts. Of those 
identified by microarrays, the individual 
transcripts of interest were typically 
among those followed up by PCR for 
validation purposes. 
 
On TC in discussion with R# 4, agreed that 
no changes were needed to address 
genomewide profiling.  
 
 
In Chang & Doerge 2000 and 
Doerge &Chang 2002, 
genistein administration was 
shown to lead to into a 80% 
inhibition of TPO activity but 
no effects were observed on 
TH levels in rat. This should 
be added in uncertainties 
and inconsistancies 
The authors agree with this comment 
from the reviewer and altered the text 
accordingly, as suggested 
Added to page 63.  Uncertainties and 
Inconsistencies. 
 It is important to note that data from 
studies on genistein highlight this 
uncertainty. Doerge and colleagues have 
demonstrated that for this comund up to 
80% TPO inhibition did not result in 
decreased serum T4 in rats (Doerge and 
Chang, 2002). This is not consistent with 
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other prototypical TPO inhibitors (e.g., 
PTU, MMI). It remains to be determined if 
for some presently unknown reason, that   
genistein is an outlier.  
 
Two reviewers are calling for 
the inclusion of existing 
studies showing moderate to 
severe decreases in 
circulating TH, leading to 
minor or undetectable adverse 
effects on brain morphology 
in the offspring  
Quantitative relationship 
between the necessary 
decrease of thyroxine levels 
in dams, the resulting 
decrease of throxine in fetal 
brain and a 
neurodevelopmental adverse 
outcome is poorly understood 
and compounds with similar 
effects on thyroxine levels do 
not necessarily result in a 
comparable or  in an adverse 
outcome at all (e.g., PTU 
versus ETU, Mancozeb Case 
Study, European 
Commission, 2017). The 
different outcomes for PTU 
vs ETU are currently not 
understood, whether 
iodothyronine deiodinase type 
I inhibition by PTU might 
play a role remains open 
(European Commission, 
2017). Such a case should be 
included in the AOP and 
discussed. 
 
We agree with the reviewers that the 
quantitative relationship between serum 
thyroxine and adverse 
neurodevelopmental outcomes is poorly 
understood.  There are insufficient data 
to describe quantitative relationships 
owing not only to the state of 
knowledge of TH role in hippocampal 
morphology and the requisite 
contributions from maternal, fetal, 
neonatal sources when specific phases 
of hippocampal neuroanatomical 
development occur.  
One study is cited on page 117 of 
existing document in which standard 
morphometric indices of hippocampal 
size and volume were not detected at 
lower doses despite subsequent 
evidence of gene expression changes 
and neurodevelopmental defects in 
littermates. 
From Page 117 Indirect KER Serum T4 
to Hippocampal Anatomy - Dose-
Response Evidence: There are limited 
data available to inform the dose-
dependent nature of the correlation 
between serum THs and changes in 
hippocampal anatomy. Gilbert et al 
(2007) demonstrated dose-dependent 
declines in the expression of protein 
marker inhibitory neurons in both 
hippocampus and neocortex with 
graded exposures to PTU and resultant 
serum T4. Shiraki et al. (2014; 2016) 
report dose-dependent alterations in the 
expression patterns of several neuronal 
and glial protein markers in the 
hippocampus after developmental 
exposure to different doses of PTU or 
MMI. Gilbert et al. (2016) report dose-
dependent reductions in linear 
morphometry and volume of 
hippocampal subfields following 
Added to Uncertainties and Inconsistencies 
in Indirect KER page 117 we have added: 
In one of the few dose-response studies 
assessing hippocampal anatomy, 
alterations in simple guideline metrics of 
linear morphometry and volume of 
hippocampal subfields following 
developmental exposure to the PTU were 
largely restricted to the high dose group, 
despite alterations in downstream KEs of 
hippocampal physiology and cognitive 
function. This may result from inadequacy 
of the assessment tools or the timing of the 
observations. Similarly, in chemically 
induced serum hormone reductions of 
comparable magnitude as those induced by 
PTU or MMI, observations of hippocampal 
morphology are not always seen (PTU vs 
ETU or mancozeb, European Commission, 
2017).  Consideration of the sensitivity of 
neuroanatomical and neurobehavioral 
method used, as well as chemical kinetics 
that drive the reduction of maternal, fetal, 
or neonatal TH reduction, may be key to 
understanding these discrepancies.  
 
Added to Appendix Table: 
Some inconsistencies may arise when using 
maternal serum to predict offspring 
outcome on hippocampal anatomy if the 
kinetics of the chemical to not sufficiently 
reduce maternal hormones at the 
appropriate time, not cross the placental 
barrier to sufficiently disrupt fetal hormone 
synthesis, or are not sufficiently available 
to the nursing pup via the milk (European 
Commission, 2017) 
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developmental exposure to the PTU. 
 
“reduction of thyroxine levels 
with genistein were not 
associated with cognitive 
impairment unless an iodine 
deficiency exists’ 
Discussion with the Lead Reviewer 
stated that this comment was a cut and 
paste error and there is not paper 
describing this scenario 
No changes needed 
Suggestions to add the KE 
related to local deiodination 
decreased quantifiable data 
should be added between 
levels of TH in serum and in 
brain and gene expression.  
 
The Reviewer is correct that 
deiodinases play an essential role in 
maintaining appropriate concentrations 
of TH in brain and other organs. We 
agree that this AOP, as well as most 
AOPs, have ‘missing’ steps.  For this 
AOP there could be multiple steps 
added for complete TH synthesis 
pathway, as well as steps for release 
from thyrocytes, uptake from blood into 
tissues via cellular transporters, 
interaction with serum binding proteins, 
etc.  We have included 
acknowledgement of the importance of 
deiodinase in the TH regulatory system 
several places in the current document, 
specifically addressing deiodinases in 
KER  _T4 in Serum to T4 in Neuronal 
Ttissue.  
Page 37: Within the astrocyte, T4 is 
converted into T3 via the local activity 
of deiodinase 2 (DIO2) (Guadano-
Ferraz et al., 1997).  A small amount of 
T3 may cross the blood brain barrier 
directly via the T3-specific transporter, 
MCT8 (Heuer et al., 2005). Although in 
mature brain T3 derives partially from 
the circulation and from the 
deiodination of T4, in the fetal brain T3 
is exclusively a product of T4 
deiodination (Calvo et al., 1990; 
Grijota-Martinez et al., 2011). In both 
cases, only the required amount of T3 is 
utilized in neurons and the excess is 
degraded by the neuron-specific 
deiodinase DIO3 (Tu et al., 1999; St. 
Germain et al., 2009; Hernandez et al., 
2010). 
Both deiodinase and transporter 
expression in brain peak in different 
To address the Reviewers concern, the 
following sentences were added to the text 
on page 82 under Uncertainties and 
Inconsistencies: 
The role of local deiodination is an 
uncertainty.  
In addition, future work on cellular 
hormone transport mechanisms and 
deiodinase activity is likely to inform the 
addition new KEs and KERs between serum 
and brain T4.  
 
And to Appendix I Summary Table 2.  
 
  Other uncertainties include:  
compensatory mechanisms can influence 
local neuronal availability of T4 and these 
relationships have not been clarified; and 
there are other know steps between serum 
T4 and brain T, including cellular 
transporters and local tissue deiodinases. 
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brain regions at different times in fetal 
and neonatal life (Kester et al., 2004; 
Bates et al., 1999; Muller and Heuer, 
2014; Heuer, 2007). Collectively, these 
spatial and temporal patterns of 
transporter expression and deiodinase 
activity provide exquisite control of 
brain T3 available for nuclear receptor 
activation and regulated gene 
expression. 
Page 80: In astrocytes, T4 is then 
deiodinated by Type II deiodinase to 
triiodothyronine (T3) (St Germain and 
Galton, 1997), which is then transported 
via other iodothyronine transporters 
(e.g., monocarboxylate transporter) into 
neurons (Visser et al., 2011). While 
some circulating T3 may be taken up 
into brain tissue directly from blood 
(Dratman et al., 1991), the majority of 
neuronal T3 comes from deiodination of 
T4 in astrocytes. Decreases in 
circulating T4 will result in decreased 
brain T3 tissue concentrations. It is also 
known that Type II deiodinase can be 
up-regulated in response to decreased 
T4 concentrations to maintain tissue 
concentrations of T3 (Pedraza et al., 
2007; Lavado-Autric et al., 2013; Morse 
et al., 1986), except in tanycytes of the 
paraventricular nucleus (Fekete and 
Lechan, 2014). 
 
If no quantitative data 
supports the current KER in 
the AOP, there is a suggestion 
to mention “no data” 
 
This is not an option in the AOPWiki as 
strength indicators are dictated by 
OECD’s AOP Handbook and guidance 
document. 
Quantitative calls remained as ‘Weak’ 
where no quantitative data are available 
Quantifiable data should be 
added between levels of TH 
in serum and in brain and 
gene expression.  
 
There is a data gap for quantitative 
understanding of hormones in serum 
and hormones in brain and for 
hormones in brain and gene expression 
in hippocampus. We have revised the 
AOP on page 83 on to address this. 
Page 83 KER serum T4 to neuronal T4 – 
Quantitative Understanding of Linkage. 
Standardization of analysis for these KEs is 
crucial to allow comparisons to be made 
between independent experiments and 
better judge the effects of changes in TH 
levels in serum and brain. Due to very low 
levels in brain, regional specificity of TH 
are not feasible in rodent studies with 
current detection methods. 
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Hippocampus anatomy 
altered 
R#4 mentions that the 
methods available to measure 
this KE are not specific 
enough. Focus must be on 
thyroid hormone specific 
alterations of the anatomy of 
the hippocampus.  
 
 
The authors disagree for a number of 
reasons.  
An AOP is not supposed to be a “how-
to” paper, but instead a review of what 
is known. Proscriptive information of 
dissection techniques or specific 
anatomical preparations are not within 
the scope of the AOP. Additionally, the 
Handbook explicitly states that each KE 
is to be independent described and 
standalone, so descriptions of “TH-
dependent” hippocampal 
neuroanatomical alterations in the KE 
section are not warranted. Finally, as 
with many of the KEs within this AOP, 
the type of anatomical change observed 
will depend on the severity, duration, 
timing of the TH reduction. Some 
phenotype may derive from maternal 
TH insufficiency, others from maternal 
and fetal, others from neonatal, and 
some may require sufficient TH 
deprivation over the fetal and neonatal 
time periods.  
 
There appeared to be a general consensus 
on the teleconference of the authors’ 
response and that no changes are needed.  
 
Hippocampus anatomy 
altered 
There is a suggestion to add a 
small section on the 
importance of maternal 
thyroid status for 
hippocampal development, 
suggestion meeting request in 
MIE section on fetal TPO 
importance. 
 
Authors agree that maternal and fetal as 
well as neonatal hormonal status may 
impact hippocampal anatomy. In 
responding to point from Slide 3 above 
this comment was addressed 
The following text was added to the revised 
document on page 6 in the Overall 
Assessment of the AOP under the Domain 
of Applicability – Page 6: Life stages:. The 
influence of maternal thyroid status prior to 
onset of fetal thyroid function is an 
important consideration.  
 
Page 18. Under MIE and ontogeny of TPO 
function.  
 It is noted that prior to the onset of fetal 
thyroid function, TH are still required, the 
fetus relying solely on maternal sources. 
Chemical-induced TPO inhibition can 
affect synthesis in the maternal gland and 
in the fetal gland. 
 
Page 118 – Uncertainties and 
Inconsistencies in indirect KER Serum T4 
and Hippocampal Anatomy. The role of 
direct fetal TPO inhibition contribution to 
fetal TH and subsequent changes to 
hippocampal structure and subsequent 
downstream KEs in humans is a knowledge 
gap.   
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Page 74 – Uncertainties and Inconsistencies 
KER TPO inhibition and serum TH. The 
relationship between maternal and fetal 
levels of hormone following chemically-
induced TPO inhibition has not been well 
characterized and may differ based on 
kinetics. Reductions in serum TH in the 
fetus, in rat and human is derived a 
chemical’s effect on the maternal thyroid 
gland as well as the fetal thyroid gland.  
 
As it currently stands, 
divergent opinions arise as to 
the applicability of the AOP 
for regulatory purposes.  
We are in general agreement with 
comments of the reviewers. 
As this section is ‘Optional’, authors have 
deleted it from Page 12 of the document 
BDNF is a KE in AOP54, but 
not mentioned at all in AOP 
42.  Why is BDNF not 
mentioned here?  
Our approach was to examine TH-
responsive genes in the hippocampus to 
identify the KE of this AOP. Although 
many transcripts have been reported, 
and we include a table of them in our 
document, it was our scientific 
judgement that none of them was 
sufficiently robust to ascertain it as 
pivotal for our progression in the AOP. 
Effects of TH disruption on BDNF have 
been equivocal and inconsistent. (see 
review by Gilbert and Lasley (2013) 
Developmental thyroid hormone 
insufficiency and brain development: a 
role for brain-derived neurotrophic 
factor (BDNF)? Neuroscience 239:253-
70.). BDNF does many things in the 
brain at different times in different 
regions. In our opinion, it’s link to TH 
was not sufficiently well documented to 
serve as a KE.  
 
This was discussed on the teleconference 
and agreed that AOP42 can stand without 
invoking the critical effects of TH 
decrements on BDNF 
 
These changes have been submitted by the authors May 25
th
 2018 to the reviewer panel and the 
reviewer manager. Authors also sent a new version of AOP with changes incorporated. All 
agreed that these changes were sufficient and that the AOP should be changed following these 
planed modifications.  
Authors did make the modifications and incorporated them in the AOP wiki first week of June 
2018. 
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5.  Further discussion 
 
From the review manager point of view, expectations in terms of reviewing, 
communication, organisation and reporting are now clearer than at the beginning of 
review process.  
Review manager suggests to have a common safe space on the cloud on which all 
documents, reviews and letters would be accessible. And as it is done during manuscript 
peer reviewing, he also suggests a status indicator in order to get an overview of the 
external review process. 
 
6.  Outcome of the external review 
The reviewer panel all agreed on the high quality of the work done. Before the revision 
almost all reviewers agreed on the next applicability of the AOP for regulatory purposes.  
The reviewers developed a number of suggestions and corrections that were discussed in 
joint meeting with the authors.  This discussion between the reviewers and the authors led 
to good agreement on required changes. All of these changes have now been incorporated 
into the newly revised AOP42.  All find that the revised AOP42 is ready for final OECD 
approval and for regulatory applications in a near future. 
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Annex 1: Table with reviewers’ name 
AOP title Links (wiki / 
snapshot)  
Review manager Reviewers 
AOP 42: Inhibition of 
Thyroperoxidase and 
Subsequent Adverse 
Neurodevelopmental 
Outcomes in Mammals 
https://aopwiki.or
g/aops/42 
 
Snapshot: 
[HTML]; [PDF] 
 
Internal review 
AOP 42 
 
Dr Jean-Baptiste 
Fini 
(CNRS_France) 
Dr Angela Leung (University 
UCLA_ USA) 
Dr Ellen Hessel 
(RIVM_Netherlands) 
Dr Marta Axelstad 
(DTU_Danemark) 
Dr Alexius Freyberger 
(Bayer_Germany ) 
Pr Frances Carr (University of 
Vermont_USA) 
 
Annex 2: Individual reviewers’ comments 
Reviewer #1 
AOP 42: Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes 
in Mammals 
 
GENERAL:  
This AOP is very clearly delineated with appropriate supporting scientific evidence. The direct and 
indirect relationships of the key events are well documented with excellent descriptions of the 
physiological relevance. The essentiality of the key events and the weight of evidence are convincing and 
logically described. There are no substantive changes recommended to this AOP. 
 
SCIENTIFIC QUALITY: 
 
Overall AOP incorporates relevant scientific literature to support the relationship between the MIE, 
inhibition of TPO, reduction of neuroanatomical development and neurological function. The evidence 
provided supports the biological plausibility of the pathway and associated classification of the stressors. 
Numerous studies across species, including humans, have demonstrated that inhibition of TPO directly 
reduces TH synthesis and serum thyroxine and corresponding decreases in various regions of the brain. 
The evidence is strong that reduced serum T4 alters hippocampal gene expression.  
  
MOLECULAR INITIATING EVENT 
 
Disruption of TH synthesis may be a result of several different MIEs including dietary factors, iodine, 
inhibition of iodide transport through NIS, and direct inhibition of TPO. That differential storage of TH 
precursor and iodine varies with life stages as well as species is recognized in this AOP. The impact of a 
reversible TPO inhibitor will differ between adults with high storage capacity and neonates with low 
storage capacity. The impact of TG antibodies or age at MIE exposure could be more specifically 
addressed here as well as at Key Events. Should the importance of THRs in mediating TH action in the 
brain be noted throughout this AOP? There is not a discussion of non-genomic actions of TH in cell 
signaling in the brain. Aren’t these key events in mediating hippocampal development and gene 
expression? 
e.g.:  
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 Brent GA. 2012 Mechanisms of thyroid hormone action. J Clin Invest 122:3035-3043 
 David PJ, Goglia F, Leonard JL. 2016 Nongenomic actions of thyroid hormone. Nature Reviews 
Endocrinol. 12:111-121. 
 Flamant F, Gauthier K, Richard S. 2017. Genetic investigation of thyroid hormone receptor 
function in the developing and adult brain. Curr Topics Develop Biol. 125:303-335. 
 
The classification of the evidence is appropriate. 
 
KEY EVENTS 
 The classification of the evidence in support of upstream event(s) leading (directly/indirectly) to 
downstream event(s) is justified adequately. AOPs referencing the relationship of TPO inhibition 
leading to decreased TH synthesis and subsequent adverse neurodevelopmental outcomes in 
mammals is consonant with the key events identified subsequent to inhibition of NIS. The key 
event relationships are strong. 
 
 McMullen et al. 2017 that adolescents, both male and female, are more sensitive to exposure 
than are adults. This study clarifies that correlation between perchlorate, thiocyanate and serum 
T4 levels and notes again the absence of significant change in TSH. PMID: 28430972 
 
KEY EVENT RELATIONSHIPS 
1. The KERs of TH synthesis, serum T4 and brain concentrations of T3/T4 are particularly well 
described with appropriate supporting evidence. 
 
2. Since this AOP was developed, additional studies further strengthen the relationship between thyroid 
hormone levels and neurogenesis and hippocampal development. 
 
 The impact on hippocampal neurogenesis of impaired thyroid during developmental but not adult 
periods emphasizes age-related vulnerabilities.  
Gilbert ME, Goodman JH, Gomez J, Johnstone AFM, Ramos RL. 2017 Adult hippocampal 
neurogenesis is impaired by transient and moderate developmental thyroid hormone disruption. 
NeuroToxicology 59: 9-21. 
 
 The KER of decreased T4 in serum and decreased T4 in neuronal tissue is plausible.  Given the 
compensatory mechanisms to maintain adequate and not excessive T4/T3 in brain tissue, the 
degree to which decreased serum T4 directly corresponds to quantifiable decreased T4 in 
neuronal tissue is not yet clear. Should this be more directly stated? Nevertheless, that decreased 
serum TH results in lower brain TH concentrations is well established.  A recent review of TH 
signaling and neurogenesis across species may strengthen this KER. 
Gothie J-D, Demeneix B, Remaud S. 2017 Comparative approaches to understanding thyroid 
hormone regulation of neurogenesis. MCE 459:104-115. 
 
 Bernal J. 2017 Thyroid hormone regulated genes in cerebral cortex development (Review). J 
Endocrinol 232:R83-R97. 
 
Overall, the uncertainties or inconsistencies are appropriately noted.  The limitations of the quantitative 
understanding of the KE linkages are addressed.  
 
Weight of Evidence 
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MIE Evidence supports the classifications.  Given more recent studies, the evidence in support of 
lifespan applicability is growing.  The potential for indicating the evidence is strong rather than moderate 
should be considered (page 2). The scoring within the AOP for KEs, KERs is consonant with the 
evidence cited.  Additional references such as provided above can strengthen the evidence however; the 
critical citations have been included already. 
 
 
Regulatory Applicability 
 
Since the AOP covers endpoints that are measured using widely accepted methods, including TPO 
activity, TH levels and neurodevelopmental outcomes, it is highly probable that it will have broad 
regulatory applicability. This AOP can provided the basis for standardizing evaluation of classes of 
chemicals and their biological impact. The weight of evidence and classifications of the KEs and KERs 
provides an important framework to guide policy/regulatory development. Inhibition of TPO can be 
reversible. Thus, the timing of exposure, the length of exposure should be considered in any regulatory 
framework. 
 
Conclusion 
 
The AOP is very well developed.  The revisions suggested provide possible enhancements to the AOP 
but the central tenets are strong and well supported.  
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Reviewer #2 
OECD, AOP External review: Reply to charge questions  
 
In general, a lot of hard and very relevant work has been put into the making of these two AOPs. 
I however find that it weakens the concept and regulatory use of the AOP concept when two 
AOPs which both have a common KE (low TH in serum) and the same AO (impairment in 
learning and memory) are so different and do not share the same (or only very few of the same) 
KEs and KERs. I find that this issue should be discussed further in the review group and with 
OECD. 
 
Below, please find my review of AOP 42.   
 
AOP 42: Inhibition of thyroperoxidase and subsequent Adverse Neurodevelopmental 
Outcomes in Mammals 
 
Scientific quality: 
Does the AOP incorporate the appropriate scientific literature, and does the scientific content of the AOP 
reflect current scientific knowledge on this specific topic? 
 
I find that this AOP incorporates almost all relevant scientific literature (of which I am aware). I can only 
think of a few issues which I do not find that the authors have been dealt with in enough detail. 
 
1) In the AOP 54, a lot of emphasis is put on the importance of BDNF (levels and expression) in relation 
to neurological development. Many of the cited papers are form the group of Dr. Gilbert, showing 
reduction in BDNF in developmentally hypothyroid animals. If this is indeed a common finding in 
hypothyroid animals and this factor is important for neurological development, I find that it would be 
informative to include this information in the present AOP. If, on the other hand, the authors of the 
present AOP (after evaluating all the available data on this endpoint), do not find this KE to be crucial for 
adverse brain development in relation to hypothyroidism/hypothyroxinemia, I believe that this should be 
better reflected in AOP 54.   
 
2) Some places the authors state that the KERs they describe are strong, because they are ’accepted 
dogmas within the scientific community’ or ‘well accepted in endocrinology’. These statements are 
however not always substantiated with references or study descriptions, in the ‘biological plausibility’ 
paragraphs. That something is an “accepted dogma” is not an argument, so please revise by 
substantiating all these sorts of statements with study references (for instance on p 39 and 62). 
 
3) The issue of quantitative predictive models linking serum TH concentrations to adverse cognitive 
outcomes is in my view not fully discussed. It is stated several times that this correlation has not been 
performed (or only performed for hearing loss) due to lack of studies examining this. Furthermore the 
authors state that “the occurrence of the final AO when upstream key events are observed is extremely 
consistent” (p 66). While these statements may be partially true, I believe that the authors should in this 
AOP also include studies from the open scientific literature, showing cases where moderate to severe 
decreases in circulating thyroid hormones levels in pregnant dams, only lead to minor or no detectable 
adverse effects on behavior or brain morphology in the offspring. Because such examples do exist but are 
not mentioned, it may leave the reader with the impression that all cases of developmental exposure to 
TPO inhibiting chemicals will cause adverse DNT effects, even though we don’t know whether this is 
actually the case - because it has only been shown consistently with MMI and PTU.  
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4) The human link between thyroid hormone decrease during development and adverse neurological 
outcomes, and especially the aspect of quantification of T4 decreased is in my opinion not discussed in 
enough detail. For instance only one study (Haddow et al 1995) is cited on page 62 where this issue is 
discussed, even though much more literature examining the relationship between maternal T4 levels and 
neurological outcome in the children is present in the open literature (Haddow et al. 1999, Pop et al. 
1999, Kooistra et al. 2006, Li et al. 2010, Henrichs et al. 2010, and more…). I find this very important, 
because the better the presently available knowledge from humans is described, the easier it will be to 
link a %-decrease in T4 (in an animal study) to a likely adverse neurological effect, without even having 
to perform the neurological assessment in vivo. 
 
 
Weight of evidence:  
Are the weight-of-evidence judgement/scoring calls provided by AOP developers for KEs, KERs and the 
overall AOP justified? 
 
In general yes, with the few exceptions mentioned above.  
 
Additionally, on page 29, in the table with scientific evidence supporting the linkages in the AOP, I find 
that a step is missing when the authors state that “Decreased T4 in neuronal tissue” directly leads to 
“altered hippocampal gene expression”. I think that it should be reflected in the table and in the AOP 
description in general (possibly as a KE)  that there is an important step in between (i.e. local deodination 
of T4 to T3 which then binds to the TRs and causes the altered gene expression). And since the action of 
the deiodinases can be upregulated in cases of low T4, so that more T4 is converted to T3 in order to 
compensate for the lower T4 availability, low neuronal T4 levels may not in all cases lead to altered gene 
expression. I therefore find that the “local conversion of T4 to T3 – step” should be included in the AOP 
description.  
This issue is also discussed on p. 39, in the “weight of evidence section”. Here I find that some more 
clear references to the studies actually measuring the link between serum TH concentration and brain TH 
concentrations (prior to the empirical support for linkage section) would add value to the description. As 
long as they are not provided, it is difficult for the reader to determine whether the WoE link is 
“moderate” and the “biological plausibility” for this KER is strong, as stated by the authors. I realize that 
the available empirical support is referred to in the next paragraph, but here I find that it would be useful 
to divide the references into those showing proportionality between the TH levels in serum and the brain, 
and those investigating this relationship in other tissues. 
 
Overall, I find that the section on page 66-67 on uncertainties, inconsistencies and data gaps is very well 
written and includes many of the key uncertainties of using this AOP. I do feel that it should be specified 
that the adverse developmental neurotoxicity effects seen in the few cited studies using other compounds 
than PTU and MMI (PCB, BPA and TBBPA), may not have anything to do with changes in thyroid 
hormone levels during development, but could be effects occurring due to disturbances in other 
endocrine systems or be caused by direct neurotoxic effects of these chemicals.  
 
Regulatory applicability:  
Considering the strength of evidence and current gaps / weaknesses, what would be the regulatory 
applicability of this AOP, in your opinion? 
 
I find that this has been very nicely explained in the present AOP in the weight of evidence summary on 
pages 65-69. I agree with the authors when they state that until we have a quantitative relationship 
showing;  
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1) To what extent TPO inhibition in vitro has to be affected  in order to elicit a T4 decrease  in vivo 
2) To what extent circulating T4 levels must be decreased (in dams and in offspring at different 
developmental stages) before adverse effects are observable in behavior and morphological brain 
differentiation 
  
we can only use QSAR or in vitro data for TPO inhibition to prioritize chemicals for further testing. This 
means that based on the present AOP we cannot presently predict which compounds predicted or found 
to act as TPO inhibitors (in QSAR models and in vitro batteries) wil indeed cause adverse effects on 
brain development.   
 
Conclusion:  
What are your overall conclusions of the assessment of this AOP? 
 
The AOP is well written, thorough and well augmented, except for the few exceptions which I have 
stated previously. 
 
 
Below are my smaller, additional comments for revision of this AOP: 
 
P12. Line 12. The word “is” is missing in the sentence starting with “In serum, it is the …of the hormone 
that is thought to be ….”  
 
P 15, line 8 from bottom: please delete the word “as” in the following sentence: In the rat, either whole 
brain or cortex have been preferentially assessed as due to the low… 
 
P19, line 6: please include a “space” in the between the words “phases” and “can”, in the sentence Tables 
of gene clusters associated with these phasescan… 
 
P 19,section  “How is it measured”. It would be helpful to include a sentence or two about how large the 
overlap is between gene expression profiles in the three mentioned species (humans, non-human primates 
and rodents). Are the same genes affected in all three species, are there no overlaps, or are we 
somewhere in between.   
 
P 19,section  “How is it measured”. The last sentence of the paragraph is the first time in the entire 
section that the TH regulation of this process is mentioned. Since at least 7 of the references connected to 
this KE description are in studies investigating TH related effects, some more information about this in 
the text would improve the description. 
 
P20-22: KE 757 is called “Hippocampal anatomy, Altered” but in reality the KE explains hippocampal 
anatomy, but not how it may be altered. Therefore please provide some information about the effects on 
hippocampal anatomy when TH levels are decreased in the KE description. 
 
P 21, How this key event works, line 6. Pleas add an “s” in the word “it” in the sentence “Dentate gyrus 
forms in late gestation with most of its development… 
 
P 23-25 KE 758. There is no mentioning of the role of thyroid hormones in the section “How this key 
event works”, and this issue is only touched upon briefly in the “How is it measured or detected” section. 
Please expand a little bit more regarding the role of TH in this KE.  
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P28 “regulatory examples using this AO”. The Bellinger 2012 paper that is referred to is in my opinion 
not an example of “regulatory use”. I would rather suggest to exemplify using references to regulatory 
reports (EFSA, ECHA, FDA EPA) where regulatory action has been taken (classification, restriction of 
use) based on decreased cognitive function caused by developmental exposure to a chemical. 
Furthermore, the next sentence is a repetition of content already stated in the previous section (p  27 line 
3-6 from bottom). 
 
P31, last paragraph before the references: It would be valuable if the authors could explain in a bit more 
detail what they think of this finding from the Chang and Doerge 2000 study. It this lack of in vivo effect 
on T4 after an 80% TPO inhibition a normal response ? Was the genistein maybe metabolized to 
compounds which are not TPO inhibitors or what was the explanation of the study authors to this 
phenomenon – and how do the AOP authors reflect upon this finding ? 
 
P33, line 13. Please delete the “a” in the sentence: “ a Furthermore… 
. 
P40 “qualitative understanding of the linkage”. Is the qualitative linkage between TH levels in serum and 
in other tissues not shown in any of the papers cited on the previous page (empirical support section)? If 
this is indeed the case, please expand a little bit on this issue. 
 
P 42, weight of evidence, last sentence. It is stated that studies are limited, but no references are 
provided. If indeed there are some studies showing this please provide citations. If no studies are 
available please state that this is the case.  
 
P65, line 2 from bottom. Please add the word “is” in the sentence : It is also….” 
 
A full reference list of all used references would be nice to have, 
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Reviewer#3 
1.      Scientific quality 
 Does the AOP incorporate the appropriate scientific literature? 
 Does the scientific content of the AOP reflect current scientific knowledge on this specific 
topic? 
  
I have reviewed the AOP snapshot and responses from the authors to the previous reviewers’ 
comments in preparation for this external review.  The broad hypothesis of AOP 42 is based on the 
strong scientific evidence that thyroid hormone is critical for normal neurodevelopment, such that the 
MIE of thyroperoxidase inhibition results in several KEs corresponding to decreased thyroid hormone 
availability and hippocampal defects to result in the AO of decreased cognitive function (specifically the 
components of decreased learning and memory; and decreased cognition).   
This revised AOP is well-written, comprehensive, and in a very systematic approach, addresses 
the complexity of the potential adverse effects of thyroperoxidase (TPO) inhibition.  The authors are 
established scientists and regarded experts on this topic, and a significant amount of the original work on 
this topic has been published by several of the authors themselves.   
The specified KE are comprehensive, but as the authors state, current gaps in knowledge 
regarding the complexities of brain development remain in this pathway.  Decreased cognitive function is 
a relatively broad term which can refer to variety of adverse clinical measures (i.e. IQ, 
neuropsychological tests, behavioral tests, others).  Thyroid hormone-dependent actions in the brain 
include neuronal migration, dendritic arborization, synaptogenesis, axonal myelination, cortical 
volume/cytoarchitecture, cerebellar proliferation, granule cell migration, Purkinje cell maturation, and 
callosal zone projections, in addition to the hippocampal neurogenesis and volume that is focused in this 
AOP.  As such, although there are likely other KEs which can also result in the AO, the focus of this 
AOP on the hippocampus is one of the most scientifically developed in the available literature (both 
animal and human data).  I also agree with the authors that thyroid stimulating hormone (TSH) action is 
not a KE required for this pathway, since TSH has not been understood to have any direct action on brain 
development, but rather on feedback within the hypothalamic-pituitary-thyroid axis.  
Overall, this AOP describes what is known and what remains to be better understood regarding 
this pathway.  The bibliography for the AOP is complete and captures the seminal references on this 
topic.   
 
2.      Weight of evidence 
 Are the weight-of-evidence judgement/scoring calls provided by AOP developers for 
KEs, KERs and the overall AOP justified? 
 
Overall, I agree with the weight of evidence designations assigned to each of the KEs, KERs, 
and the overall AOP.  The weight of evidence supporting the MIE by methimazole and propylthiouracil, 
in addition to other agents in the environment and diet, is high.  Methimazole and propylthiouracil are 
medications used commonly in the clinical setting to treat hyperthyroidism, in order to reduce thyroid 
hormone overproduction, and have been in use as such since the 1940s.  As the developers state, there is 
a high level of evidence that AOP 42 is most relevant during early periods of neurodevelopment, and that 
the effects apply to both genders. 
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Regarding the KERs, the literature also supports the high level of evidence stated by the 
developers regarding the relationships between decreased serum thyroid hormone concentrations 
resulting in several hippocampal gene expression and anatomy.  It is well-established that decreased 
serum thyroid hormone concentrations also result in the AO.  I agree that the current understanding 
regarding the other KERs is less robust and supported by a moderate weight of evidence.   
 
3.      Regulatory applicability 
 Considering the strength of evidence and current gaps/weaknesses, what would be the 
regulatory applicability of this AOP, in your opinion? 
 
The two points presented in the Considerations for Potential Applications of this AOP would be 
supported by the evidence presented.  As Integrated Approaches and Testing Assessment (IATA) 
strategies take into account an acceptable level of uncertainty and not all of the intermediate KEs need to 
be quantified, this AOP would provide the necessary initial components to generate a computational 
model.  It is reasonable to also utilize this AOP to support development of a high throughput screening 
assay detecting other thyroperoxidase inhibitors that have been proposed from in vitro data. 
 
4.      Conclusion 
 What are your overall conclusions of the assessment of this AOP? 
 
I believe that AOP 42 is well-prepared and has been comprehensively organized by established 
scientists who have the appropriate background and expertise on this subject.  Although the action of 
TPO inhibition on the hippocampus likely represents just one of the many effects of thyroid hormone on 
the brain, the available strength of evidence is appropriate justification to focus on it as a mediator 
toward decreased cognitive function.   The AO is complex, and the clinical outcomes encompassing it are 
broad, thus there are still uncertainties which surround this AOP.  Overall, the developers have nicely 
captured what is currently known about this pathway. 
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Reviewer#4 
AOP external review – 2018 – AOP 42 Inhibition of Thyroperoxidase and Subsequent Adverse 
Neurodevelopmental Outcomes in Mammals 
 
General comments 
The AOP includes a lot of scientific and peer-reviewed literature and clearly describes the pathway from 
the molecular initiating effect up to organ and organism effects. It would be helpful in general to explain 
the functioning and mechanism of the thyroid system in the beginning of the AOP with a separate figure 
that include all the aspects of thyroid functioning.  
 
1.    Scientific quality: 
•      Does the AOP incorporate the appropriate scientific literature? 
•      Does the scientific content of the AOP reflect current  scientific knowledge on this specific topic? 
 
1. For AOP 42 MIE “Thyroperoxidase, Inhibition”  
a. Mention T3 and / or T4 in the figure 1, that makes it more clear. 
b. For “how does this Key event works: please explain the ontogeny of TPO for rodents 
and humans separately. Now it is difficult to distiquish the two.  
2. For AOP 42 MIE “Thyroperoxidase, Inhibition” please refer to the OECD new scoping 
document and the references used within this document in the paragraph “how to measured or 
detected”. Title document: “New Scoping Document on in vitro and ex vivo Assays for the 
Identification of Modulators of Thyroid Hormone Signalling”. Within this document, the TPO 
assay is explained at page 32-35. If this method will be (further) validated by OECD this will 
have preference. 
3. For KE ‘T4 in serum, decreased’ (page 10-14) paragraph “how it is measured or detected”  
a. Please specify what the advantages and disadvantages are for measuring free and total 
T4 and T3 and what the preference has to measure this KE.  
b. Different techniques are mentioned to measure thyroid blood levels. Two are missing 
namely HPLC-MS and Immuno Luminescence. All the available  assays have different 
sensitivities. Therefore, results including reproducibility and repeatability really depends 
on the protocol used. Standardization of analysis for this KE is crucial to make 
comparisons between independent experiments possible and to better judge the effects in 
TH levels (Chang et al., 2007).  
c. Please mention that blood sampling should be controlled for experimental factors (such 
as circadian rhythm or food intake) that might influence the measured concentration 
measured and the variability of the hormone determination (Döhler et al., 1979). 
4. For KE “T4 in neuronal tissue, decreased”, paragraph ‘how it is measured and detected’ (page 
16). Based on the brain region specific levels it is important not to measure whole brain levels 
but also brain region specific TH levels (Constantinou et al., 2005). Please mention that the way 
of dissecting the brain regions is crucial to draw the right conclusions.  
5. For KE ‘hippocampal gene expression’ paragraph ‘how it is Measured and detected’ (page 19): 
genome wide profiles or microarray studies are not specific enough to measure the effect of TH 
levels on gene expression. This is not a specific endpoint for this KE. First it must be studied 
which genes in hippocampus will be changed by hypothyroidism and then if mRNA (rtPCR) and 
protein levels are disrupted due to the hypothyroidism. Thereafter, the role of these altered 
expression levels of the specific genes on the hippocampal anatomy must be studied in more 
detail to be more specific within this KE.    
6. For KE ‘hippocampal anatomy’ paragraph ‘how it is measured or detected’ (page 22) the 
methods are not specific enough. Focus must be on thyroid hormone specific alterations of the 
anatomy of the hippocampus (now it is only described how to measure the anatomy of the 
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hippocampus, but no link can be made with thyroid hormone levels and what the anatomical 
changes are) (Koromilas et al., 2010).  
7. For AOP 42 KE ‘hippocampal gene expression’ and ‘hippocampal anatomy’ and the KER 
between the two: 
a. Nothing is mentioned for this KE about the role of maternal T4 levels on the gene 
expression and the development of the hippocampus, but the prenatal period including 
thyroid levels are crucial for normal hippocampal development (Moog et al., 2017; 
Willoughby et al., 2014).  
 
2.     Weight of evidence:  
•      Are the weight-of-evidence judgement/scoring calls provided by AOP developers for KEs, KERs 
and the overall AOP justified? 
 
For AOP 42 the weight of evidence  
a. In the weight of evidence for the KER between ‘Hippocampal Physiology Altered’ leads 
to ‘Cognitive Function’ the cognitive function is mentioned as episodic memory. Please 
specify what the relation is between episodic memory and cognitive function.  
b. a clear scientific link between thyroid hormone levels in hippocampus, hippocampal 
gene expression, and hippocampal anatomy is missing. Therefore, the empirical support 
of the two KER in between these KE are determined by the authors as moderate. The 
reviewer agrees with the author but even think that this is weak. Gene expression 
changes can in some cases affect the anatomy of the hippocampus, but it is not clear 
which genes are involved and how alterations in these genes affect the hippocampal 
anatomy. Additionally it is unclear how thyroid hormone levels in the hippocampus will 
affect gene expression in the hippocampus and how that will affect the hippocampal 
anatomy. More scientific evidence is needed. This is the weakest point of this AOP. The 
other KE and KER are better supported by scientific data. The scientific evidence for 
this AOP and the studies referring to the indirect KERs are much stronger therefore, 
unless these huge uncertainties between these KE, this AOP is very interesting, good 
designed and obvious to occur (also based on the available epidemiological evidence).  
 
3.     Regulatory applicability:  
•      Considering the strength of evidence and current  gaps / weaknesses, what would be the regulatory 
applicability of this AOP, in your opinion? 
 
This AOP can be used for developmental (neuro) toxicity and for identification of endocrine disruptors 
(thyroid disruptors). Additionally, this AOP can be used and help to unravel the mechanisms of thyroid 
hormone disruption and the occurrence of a decrease in cognitive functioning in mammals. Therefore, it 
is probable that it will be applicable for mechanistic tests as part of an IATA. The AOP is very 
interesting since it describes and important aspect of thyroid disruption for which many epidemiological 
evidence is available. At this stage it is still difficult to take a regulatory decision based on this AOP, 
since further development and more scientific data underlying the KE and KERs for the AOP are needed. 
As soon as it is applied for prioritization, more data will become available for the individual KEs/ KERs 
 
4.    Conclusion:  
•      What are your overall conclusions of the assessment of this AOP? 
 
I would recommend this AOP for submission since an AOP is intended to be a constantly developing 
document, the adverse outcome is very important and proven to occur after hypothyroidism. It nicely 
links epidemiological evidence with the mechanistic data. The AOP is very useful and obvious to occur 
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based on the indirect KEs. However, more research is needed on the specific effect of TH levels on gene 
expression in the hippocampus and how that gene expression specifically affects the hippocampal 
anatomy and functioning. The descriptions and alterations are not specific enough and too limited yet. 
Additionally, more standardization to measure TH levels is needed in future.  
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Reviewer #5 
Scientific Quality 
In general the pertinent literature is cited, however, in some cases conflicting papers that challenge the 
adverse out pathway are missing and/or need to be discussed. The current understanding of chemicals’ 
interactions with TPO is not adequately covered, when using the term “Thyroperoxidase Inhibition” as 
this term – if used in a strict sense – dose not cover all of these mechanisms. Information dealing with the 
treatment of human fetal thyrotoxicosis and pointing to a potential role of fetal TPO inhibition should be 
included. Details are given below: 
Event 279 - Key Event Title: Thyroperoxidase Inhibition 
In the light of the current text and explanations in the AOP the title “Thyreoperoxidase Inhibition” is 
misleading and with regard to certain types of interaction even incorrect. An adaptation of the wording is 
necessary to correctly cover the current understanding of interactions with thyroid peroxidase-catalyzed 
reactions. 
Rationale: 
The biochemistry of haloperoxidases is complex. For TPO two different catalytic cycles that have one 
element in common are described. 
Cycle 1: TPO is oxidized by hydrogen peroxide to form Complex I. Stepwise reduction (one electron 
reductions) of Complex I via Complex II restores TPO in the initial state. Complex I and probably 
Complex II play an important role in the coupling reaction. They can also oxidize foreign compounds to 
radicals that can be lethal to the enzyme. 
Cycle II: TPO is oxidized by hydrogen peroxide to form Complex I. Complex I then combines with 
iodide to form the TPO iodinating spezies (by many researchers addressed as enzyme localized 
hypoiodous acid). The TPO iodinating species iodinates tyrosine contained in thyroglobulin to form 
mono- and dioiodotyrosone. 
The following ways of interaction of a chemical with TPO-catalyzed reactions are thus possible and have 
been described: 
a) Formation of a reversible complex with TPO that inhibits TPO enzyme → reversible inhibition 
b) Oxidation by complex I or II to a radical that bounds covalently to TPO and destroys TPO 
enzymatic activity → irreversible inhibition 
c) Preferred iodination by TPO-iodinating species instead of iodination of tyrosine contained in 
thyroglobulin 
d) Redox reaction with TPO-iodinating species, the chemical is oxidized by the TPO-iodinating 
species resulting in oxidized chemical, iodide and TPO in the resting state. No iodination of  
tyrosine contained in thyroglobulin occurs. 
The following scheme shows the catalytic cycles and the interaction types b and c for genistein (from 
Diwi et al., 1997) 
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Interaction types c and d do not involve inhibition of TPO enyme, they rather inhibit the outcome of the 
desired reaction, namely iodination. 
An example for chemicals interferring according to type c represents Biochanin A which is  is an 
excellent substrate for iodination and is preferred by TPO-iodinating species. Iodination of biochanin A 
occurs exclusively as long as biochanin A is presend: 
 
Once all Biochanin A is iodinated, iodination of tyrosine (formation of mono-iodo-tyrosine (MIT) in the 
experimental model shown below, re-occurs. With increasing concentrations, MIT formation is 
suppressed for an increasing time period. After suppression the rate of re-appearing MIT formation is 
comparable to the control rate (from Diwi & Doerge, 1996). 
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The scenario is comparable for compounds that undergo redox reactions with TPO-iodinating species 
such as ethylenethiourea (ETU). However, the chemical is not iodinated, but oxidized (Doerge & 
Takazawa, 1990) 
Accordingly, interactions with TPO exist that are generally not covered by the term “enzyme inhibition” 
in general or “Thyroperoxidase Inhibition”  in the special case. It is important in this context that in vivo 
(rat) propylthiourea (PTU) is considered to interact according to type d (Taurog & Dorris, 1989). 
The term “Thyroperoxidase Inhibition” is thus very problematic, it may be replaced by another one, but 
in practical terms it may be more simple just to exlain in the beginning of the AOP that in the context of 
the AOP “Thyroperoxidase Inhibition” also covers interactions with the TPO-iodinating species that may 
not be addressed by “Thyroperoxidase Inhibition” if used in a strict classical sense. 
Key event component: Iodide Peroxidase Activity – Thyroid Peroxidase – “Decreased”  
Regarding  above mentioned interaction types c and d, TPO enzyme activity is not inhibited/decreased, it 
is the desired outcome, thyroid hormone synthesis, which is decreased. Thus, the wording must be 
changed.  
Proposal: Instead of “Decreased” use “Activity Decreased or Iodinating Species Trapped.”  
List of Stressors 
For a given compound only one spelling should be used. Currently several options are given (e.g., 
ethylenethiourea and ethylene thiourea). To allow unequivocal identification  CAS numbers could be 
given for all compounds. 
Taxonomic Applicability 
TPO is certainly a MIE that is conserved across taxa, however, it would also be worthwhile to address 
(potential) species differences regarding sensitivity to TPO inhibition. Systematic investigations in this 
field are urgently missing. The very limited work available, however, suggests that depending on 
species/class of compound huge differences may exist. Takayama et al. (1986) showed that cynomolgus 
monkey TPO (used as a surrogate for human TPO) was at least 450-times less sensitive towards 
inhibition through sulfamonomethoxine compared to rat TPO. In line with this biochemical observation 
sulfamonomethoxine (270 mg/kg for 5 weeks) decreased T4, increased TSH and thyroid weight and 
induced thyroid hyperplasia in the rat, whereas no such finding were observed in cynomolgus monkey 
(270 mg/kg, 5 weeks) (Takayama et al. 1986). A strong inhibition by a given compound in one species 
may result only in very weak inhibition in another one and would thus not result in an adverse outcome.  
Event 277 - Key Event Title: Thyroid hormone synthesis, Decreased 
 
Taxonomic Applicability 
It appears to be unlogic if under event 277 less species are mentioned than under event 279.  
Chemistry 
Occasionally, propylthiouracil (PTU) and methimazole (MMI) are both addressed as thiouracil 
derivatives, however, MMI is a imidazole derivative. 
 
Other Considerations - Kinetics 
There is old data suggesting that the reason for the strong effect of thiorureylene compounds like PTU 
and MMI on thyroid hormone synthesis is active accumulation in the thyroid (summarized by Neary et 
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al., 1984). Also for other compounds active uptake into the thyroid is speculated as prerequisiste for anti-
thyroid action (Weisberger, 1983). These considerations are possibly beyond the scope of this AOP, but 
inclusion may be helpful and could be considered. 
Other Considerations - TPO Inhibition in fetal thyroid gland 
Both PTU and MMI used most as pharmacological tool to decrease thyroid hormone levels have a 
proven history in the treatment of human fetal thyrotoxicosis, i.e., they are able to cross the placenta 
(Kurtoglu & Özdemir, 2017). Given the fact that these compounds are accumulated in the thyroid (Neary 
et al., 1984), they also should interfere with thyroid hormone synthesis in fetal thyroid. Even if the fetal 
thyroid in the rat is only active for about 5 days(in human it is many months) until birth it contributes to 
the overall thyroxine level in the fetus and a inhibition of fetal hormone synthesis should contribute to 
neurodevelopmental toxicity. The ability of compounds to reach the fetal thyroid or not could be an 
important discriminator for TPO inhibitors regarding neurodevelopmental toxicity. I am unaware of any 
studies dealing with this aspect, however, this knowledge gap should be addressed. 
Although not explicitly mentioned, the AOP rather implies effects on maternal serum thyroxine levels 
through TPO inhibition. Clarification is needed regarding fetal TPO inhibition.      
 
Weight of Evidence (WoE) 
In general, WoE assessments and scorings are appropriate. If quantitative data are lacking, this should be 
clearly stated. There are cases of inconsistency that are not discussed in the AOP. At present, there are 
also no rules describing how an inconsistency would affect scorings. Such an approach should be 
developed. Further details are provided below:  
For two Key Event Relationships it is stated in the AOP that no quantitative data are available: 
Thyroxine (T4) in neuronal 
tissue, decreased 
directly leads to hippocampal gene expression, 
altered  
Hippocampal gene expression, 
altered  
directly leads to hippocampal anatomy, altered 
Accordingly, regarding quantitative understanding rather “No Data” than Weak” is the proper qualifier. 
 
There is inconsistency regarding  
Thyroperoxidase, inhibition indirectly leads to T4 in serum, decreased 
Strong inhibition of TPO activity is obviously not for all chemical classes necessarily associated with a 
reduction of circulating thyroid hormone (TH)  levels. Following administration of genistein resulting in 
a reduction of ex vivo measured TPO activity by more than  80%, no effects on THs or TSH serum levels 
were observed in rats (Chang & Doerge, 2000; Doerge & Chang, 2002), although the rat is considered to 
be a very sensitive species regarding interference with thyroid function. Similarly, a diet rich in soy 
compared to a standard diet had little impact on biochemical and histopathological parameters of thyroid 
function in rats, unless combined with iodide deficiency (Ikeda et al., 2000). It remains open for the 
moment if genistein is a very peculiar case, or whether isoflavonoids or even resorcinol derivatives in 
general would be associated with a similar outcome. Anyhow, this inconsistency needs special 
consideration. The example of genistein may also illustrate that TPO inhibition is necessary, but not 
sufficient to result in decreased TH in serum and that additional conditions, e,g, iodide deficiency, are 
required. This aspect is also missing in the AOP. 
There is also inconsistency regarding  
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Thyroxine (T4) in serum, 
decreased 
indirectly leads to cognitive function, decreased 
Quantitative relationship between the necessary decrease of thyroxine levels in dams, the resulting 
decrease of throxine in fetal brain and a neurodevelopmental adverse outcome is poorly understood and 
compounds with similar effects on thyroxine levels do not necessarily result in a comparable or  in an 
adverse outcome at all (e.g., PTU versus ETU, Mancozeb Case Study, European Commission, 2017). 
The different outcomes for PTU vs ETU are currently not understood, whether iodothyronine deiodinase 
type I inhibition by PTU might play a role remains open (European Commission, 2017). Such a case 
should be included in the AOP and discussed. 
 
Regulatory applicability 
In its current form the AOP is problematic when it comes to regulatory applicability. Considerable 
knowledge gaps exist, and the AOP is providing no guidance how to deal with that gaps. 
Data indicating considerable differences in sensitivity of TPO from different species raise the question on 
what data regarding interactions with TPO one should rely on and make the decision “TPO inhibited” in 
a regulatory context. Ideally this would be data from studies using human TPO, however, such studies 
are rare. Studies based on rat TPO are likely to overestimate the effects compared to human TPO at least 
for certain compounds and whether the huge number of studies performed using hog TPO properly 
reflect effects on human TPO is not broadly established. 
Strong inhibition of TPO, even if demonstrable ex vivo does not necessarily translate into a decrease of 
circulating thyroid hormone levels (the ‘”genistein case”). In addition, further contributing factors may 
be necessary (e.g., iodine deficieny in case of soy constituents). In addition it is open to what extent an 
additional factor would be needed (E.g., would mild iodide deficience suffice ?). Accordingly, TPO 
inhibition alone even if demonstrated ex vivo would be an unreliable starting point for regulatory 
applicability. 
Quantitative relationship between the necessary decrease of thyroxine levels in dams, the resulting 
decrease of throxine in fetal brain and a neurodevelopmental adverse outcome is poorly understood and 
compounds with similar effects on thyroxine levels may not readily result in a comparable or  in an 
adverse outcome at all (e.g., PTU versus ETU, the “Mancozeb Case” discussed by European 
Commission, 2017). Also the role of counter regulation in fetal brain (e.g. through iodothyronine 
deiodinase type II) and its capacity is not well understood.   
Experimental manipulations used most to provoke neurodevelopmental toxicity are iodide deficiency and 
treatment with methimazole or propylthiouracil. Any of these treatments would affect maternal and fetal 
thyroid hormone synthesis. There is little, if any work that decribes the contribution of interactions with 
fetal TPO for an adverse outcome.  
Accordingly, there are still considerable knowledge gaps in general and especially in quantitative terms, 
e.g., how much interaction with/inhibition of TPO is needed in vivo to result in a subsequent decrease of 
circulating hormones, are there transporters or other mechanisms available that shuttle certain 
compounds into the thyroid and others not, to what extent must thyroxine decrease in the maternal 
circulation and then fetal brain in order to result in neurodevelopmental toxicity, is there a crucial role for 
interactions with fetal TPO and to what extent can adaptive mechanisms compensate a toxic insult. 
In my opinion, an adverse outcome only develops if the decrease of thyroxine in fetal brain exceeds a 
certain threshold that corresponds, possibly with some Caveat, to a threshold decrease in circulating 
thyroxine in dams. Neither these thresholds are clearly understood nor is there a quantitative 
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understanding how TPO inhibition potentially in dam and fetus would translate into a sufficient decrease 
of thyroxine in fetal brain.  
In the light of the many knowledge gaps and quantitative uncertainty, I do not think that the AOP in its 
current form is ready for a broad regulatory applicability. 
 
Conclusions 
The AOP lists MIE,  KEs and final adverse outcome in a logical order. 
In general the pertinent literature is cited, however, in some cases papers that challenge the adverse 
outcome pathway are not addressed. 
The KERs are not always as strong as stated in the AOP 
A peculiar weakness is the unclear quantitative relationship between necessary degree of TPO inhibition, 
the necessary decrease of thyroxine levels in dams, the resulting decrease of throxine in fetal brain and a 
neurodevelopmental adverse outcome and the lack of understanding why a similar decrease of thyroxine 
for different compounds does not lead to the same or an adverse outcome at all. 
A definition what “Thyroperoxidase Inhibition” in the context of the AOP means should be given and the 
definition should be such that all known mechanisms of interaction with TPO-catalyzed hormone 
synthesis are covered.  
In the light of the many knowledge gaps and quantitative uncertainty, I do not think that broad regulatory 
applicability is already given for the AOP in its current form. 
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Annex 3: Written response from the authors in preparation for the end of review 
Teleconference 
The review manager did have consequent email exchange with the corresponding author before 
the TC. Even though a formally written answer was not provided at that moment, the information 
needed to prepare the TC was given. Moreover AOP42 authors also attended AOP54 TC from 
the beginning and had many relevant input to  
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Annex 4: Slides presented at the TC to support discussion 
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